Moderna Earnings Call: Revenue Rebound, Legal Overhang

Moderna ((MRNA)) has held its Q1 earnings call. Read on for the main highlights of the call.

Moderna’s latest earnings call struck a cautiously optimistic tone, as management balanced a sharp rebound in revenue, tighter cost control, and major regulatory wins against a heavy litigation charge and ongoing cash burn. Executives emphasized long‑term value from the pipeline and global partnerships, while acknowledging that legal overhang and demand uncertainty will weigh on near‑term profitability.

Q1 Revenue Surges on International Demand

Moderna posted Q1 2026 revenue of $400 million, roughly $300 million higher than a year ago and above its own guidance, marking about 300% year‑over‑year growth. The quarter was heavily skewed toward overseas markets, with roughly 80% of sales generated outside the U.S. and 20% coming domestically.

Full‑Year Growth Target Reaffirmed

Management reaffirmed its expectation for up to 10% revenue growth in 2026 despite moderating COVID demand. The company said long‑term supply deals with the U.K., Canada and Australia, along with expansion of the mNEXSPIKE COVID franchise, should underpin the top line even as the product mix evolves.

Cash Costs Fall Sharply Despite Legal Hit

Excluding the litigation settlement, Moderna reduced adjusted cash costs by 26% year over year in Q1, signaling that its restructuring and spending cuts are gaining traction. The company reiterated its target for about $4.2 billion in adjusted cash costs for 2026, arguing it can keep investing in growth while tightening the cost base.

Non‑GAAP Loss Narrows as Operations Improve

On an underlying basis, non‑GAAP performance improved markedly, with net loss excluding the settlement at $0.5 billion, or $1.18 per share, more than 50% better than a year ago. Management framed this as evidence that the core business is moving toward breakeven, even though headline GAAP results remain deeply negative.

R&D and SG&A Spending Pulled Back

Research and development spending fell to $649 million in the quarter, down 24% year over year as major Phase III respiratory and CMV programs began to wind down. Selling, general and administrative costs dropped 18% to $173 million, underscoring management’s broader push to resize the organization for a post‑pandemic demand environment.

Key Regulatory Wins and Late‑Stage Pipeline Progress

Moderna highlighted two notable approvals in Europe, including mNEXSPIKE for patients 12 and older and the world’s first flu plus COVID combination vaccine for adults 50 and above. The company also advanced several late‑stage programs, kicking off Phase III trials for Intismeran in Stage 1 NSCLC and for its pandemic flu candidate mRNA‑1018, while fully enrolling a norovirus Phase III trial with data expected in 2026.

Expanding Product Portfolio Builds New Revenue Streams

The infectious disease portfolio now comprises four approved products, spanning COVID and RSV, and management sees this as the backbone of future recurring revenue. Seasonal flu shot mRNA‑1010 faces a key U.S. regulatory decision in August 2026, while further filings are planned to broaden global access to mNEXSPIKE as payers and regulators assess the new options.

Solid Liquidity and Disciplined Capital Allocation

The company ended Q1 with $7.5 billion in cash and investments, providing a substantial buffer to fund ongoing R&D and launch activities. Moderna now expects to finish 2026 with $4.5 billion to $5.0 billion in cash after planned spending and $0.2 billion to $0.3 billion of capital expenditures, signaling confidence in its liquidity runway.

Litigation Settlement Weighs Heavily on Q1 Results

A sizable litigation settlement dominated Q1 accounting, with $878 million of a $950 million cash payment recognized in cost of sales. As a result, cost of sales ballooned to $955 million for the quarter and full‑year cost of sales guidance doubled to $1.8 billion, masking otherwise improving unit economics in the underlying vaccine business.

Additional Legal Exposure Adds Overhang

Beyond the initial settlement, Moderna faces potential additional liability of up to $1.3 billion depending on the outcome of an appeal tied to government contractor immunity. Management stressed that such a loss is not considered probable at this stage, but acknowledged that the legal process could drag into 2027 or 2028, extending uncertainty for investors.

GAAP Loss Deepens Despite Operational Gains

On a reported basis, Moderna recorded a GAAP net loss of $1.3 billion, or $3.40 per share, compared with a $1.0 billion loss, or $2.52 per share, a year earlier. The widening GAAP loss was primarily driven by the litigation charge rather than deteriorating operations, but it underscores how non‑recurring items can dominate near‑term earnings optics.

Cash Burn Set to Continue Through 2026

Cash and investments slipped to $7.5 billion from $8.1 billion at year‑end 2025, and management guided to a year‑end 2026 balance of $4.5 billion to $5.0 billion. That outlook implies meaningful cash burn over the next several quarters as Moderna funds its broad development portfolio and commercialization efforts while revenue normalizes from pandemic highs.

Revenue Outlook Constrained by Demand Assumptions

The 2026 revenue plan bakes in potential declines in COVID vaccination rates and notably excludes any contribution from the standalone flu vaccine and some other pipeline assets. Management also pointed to uncertainties around pricing, reimbursement and regulatory timing for combo products, which could delay or dampen uptake in both the U.S. and international markets.

Clinical and Regulatory Timing Still a Wild Card

Investors will need to navigate a series of clinical and regulatory milestones, many with uncertain timing, including interim oncology readouts, norovirus data and key regulatory decisions. Management cautioned that shifts in case accrual, review timelines or filing schedules across geographies could influence how quickly pipeline assets translate into commercial revenue.

Guidance Highlights Modest Growth and Ongoing Investment

For 2026, Moderna guided to up to 10% revenue growth, with full‑year sales increasingly balanced between the U.S. and international markets. The company expects Q2 revenue of $50 million to $100 million, first‑half revenue of roughly $440 million to $490 million, cost of sales of $1.8 billion including the litigation charge, about $3.0 billion in R&D, $1.0 billion in SG&A, adjusted cash costs of roughly $4.2 billion and year‑end cash of $4.5 billion to $5.0 billion.

Moderna’s earnings call painted a picture of a company transitioning from pandemic windfalls to a more diversified, albeit risk‑laden, growth story anchored in vaccines and oncology. While legal charges, cash burn and demand uncertainty cloud the near term, the combination of cost discipline, a growing product base and late‑stage pipeline catalysts will be central to how the stock trades as investors weigh long‑term potential against present‑day headwinds.